EHT1864 reduced the levels of active Rac-GTP (Figure 6E and Supplementary Figure 6), but did not appreciably affect ERK, AKT, or p70S6K phosphorylation (Figure 6D); it is possible that tumor cells adapted to Rac inhibition during treatment to maintain oncogenic pathway activation, and/or the time point selected for analysis was outside the window of pathway inhibition. This evidence concerns the gene RPS6KB1 and neoplasm.